When is the next results date for Alivus Life Sciences Ltd?
2026-01-16 23:16:00The next results date for Alivus Life Sciences Ltd is scheduled for 22 January 2026....
Read full news article
Alivus Life Sciences Ltd Faces Bearish Momentum Amid Mixed Technical Signals
2026-01-14 08:03:47Alivus Life Sciences Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. Despite a recent upgrade in its Mojo Grade to 'Hold' from 'Sell', the stock faces downward pressure amid mixed technical signals and a challenging market backdrop.
Read full news article
Alivus Life Sciences Ltd is Rated Sell
2026-01-09 10:11:03Alivus Life Sciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 January 2026, providing investors with the latest insights into its performance and outlook.
Read full news article
Alivus Life Sciences Ltd is Rated Sell
2025-12-29 10:10:52Alivus Life Sciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 01 Aug 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 December 2025, providing investors with an up-to-date view of its fundamentals, returns, and market standing.
Read full news article
Alivus Life Sciences Shows Mixed Technical Signals Amid Market Volatility
2025-12-23 08:18:07Alivus Life Sciences, a key player in the Pharmaceuticals & Biotechnology sector, is currently exhibiting a complex technical profile as recent market data reveals a nuanced shift in price momentum and indicator signals. The stock’s performance contrasts with broader market trends, reflecting a period of consolidation and cautious investor sentiment.
Read full news article
Alivus Life Sees Revision in Market Evaluation Amidst Challenging Sector Dynamics
2025-12-18 10:10:41Alivus Life, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting shifts in key analytical parameters. This adjustment comes amid subdued financial trends and technical indicators, highlighting the challenges faced by the company in a competitive and evolving industry landscape.
Read full news article
Alivus Life Sciences Faces Bearish Momentum Amid Technical Shifts
2025-12-18 08:15:10Alivus Life Sciences, a key player in the Pharmaceuticals & Biotechnology sector, is currently exhibiting a shift in technical momentum as various indicators signal a bearish trend. The stock’s recent price movements and technical parameters suggest a cautious outlook amid broader market dynamics.
Read full news article
Alivus Life Sciences Sees Mixed Technical Signals Amid Price Momentum Shift
2025-12-16 08:17:51Alivus Life Sciences, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical parameters, reflecting a complex interplay of price momentum and indicator signals. Recent market data reveals a transition in trend dynamics, with mixed signals from widely followed technical indicators such as MACD, RSI, and moving averages, underscoring a cautious market stance towards the stock.
Read full news article
Alivus Life Sciences Falls to 52-Week Low Amid Market Pressure
2025-12-08 16:05:47Alivus Life Sciences has reached a 52-week low, with its stock price touching an intraday low of ₹847.5, marking a significant decline in the Pharmaceuticals & Biotechnology sector. This movement places the stock just 3.66% above its lowest price in the past year, reflecting ongoing pressures within the market and the company’s recent performance metrics.
Read full news articleAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
15-Jan-2026 | Source : BSEEnclosed please find herewith the details of Earnings Call slated for Thursday January 22 2026 from 6:00 p.m. to 7:00 p.m. (IST) for your information and record.
Closure of Trading Window
14-Jan-2026 | Source : BSEIntimation of closure of trading window from December 31 2025 to January 24 2026 (both days inclusive) for the purpose of approval of unaudited financial results for quarter and nine months ended 31st December 2025
Board Meeting Intimation for The Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended 31St December 2025.
14-Jan-2026 | Source : BSEAlivus Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/01/2026 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter and nine months ended 31st December 2025.
Corporate Actions
22 Jan 2026
Alivus Life Sciences Ltd has declared 250% dividend, ex-date: 01 Sep 25
No Splits history available
No Bonus history available
No Rights history available






